The importance of consistent FSH delivery in infertility treatment

Reproductive BioMedicine Online

Volumn 12, Issue 4, 2006, Pages 493-499

  Levi Setti, Paolo Emanuele ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Bioactivity; Consistency; Filled by mass; Isoforms; Recombinant FSH; Recombinant HCG

Indexed keywords

ERYTHROPOIETIN; HUMAN MENOPAUSAL GONADOTROPIN; LUTEINIZING HORMONE; RECOMBINANT FOLLITROPIN; UROFOLLITROPIN;

ANOVULATION; BIOASSAY; BIOLOGICAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; DRUG MANUFACTURE; DRUG PURITY; FEMALE INFERTILITY; GROWTH RETARDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOPHYSIS GONAD SYSTEM; IN VIVO STUDY; META ANALYSIS; NONHUMAN; OVARY FOLLICLE ATRESIA; OVARY FOLLICLE DEVELOPMENT; OVULATION INDUCTION; PREGNANCY RATE; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN GLYCOSYLATION; RELIABILITY; REPRODUCIBILITY; REVIEW;

EID: 33645752766     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1472-6483(10)62004-4     Document Type: Review

References (51)

1. Artiges A 1999 Alternatives to animals in the development and control of biological products for human and veterinary use. The role of the European Pharmacopoeia. Developments in Biological Standardisation 101, 29-35.
2. Bagatti G, Crisci C, Datola A et al. 2001 Characterisation and comparison of recombinant human follicle-stimulating hormones. Journal of Clinical Research 4, 91-104.
3. Balasch J, Fábregues F 2002 Is luteinising hormone needed for optimal ovulation induction? Current Opinion in Obstetrics and Gynecology 14, 265-274.
4. Balasch J, Fábregues F, Peñarrubia J et al. 2004 Outcome from consecutive assisted reproduction cycles in patients treated with recombinant follitropin alfa filled-by-bioassay with those treated with recombinant follitropin alfa filled-by-mass. Reproductive BioMedicine Online 8, 408-413.
5. Bassett RM 2005a Consistency of gonadotrophins products. Reproductive BioMedicine Online 11, 117-178.
6. Bassett RM 2005b Consistency of gonadotrophins products. Response to further comments. Reproductive BioMedicine Online 11, 393.
7. Bassett RM, Driebergen R 2004 Continued improvements in the quality and consistency of follitropin alfa, recombinant human FSH. Reproductive BioMedicine Online 10, 169-177.
8. Bristow AF, Charton E 2002 Progress and problems in the replacement of in vivo pharmacopoeial bioassays for hormones. Developments in Biological Standardisation (Basel) 111, 79-88.
9. British Pharmacopeia 2002, 2003 HMSO, London.
10. Castle P 1998 The European Pharmacopoeia and humane endpoints. In: Humane End-points in Animal Experiments for Bio-medical Research. Proceedings of the International Conference. Royal Society of Medicine Press, London, pp. 15-19.
11. Cohen SN, Chang AC, Boyer HW et al. 1973 Construction of biologically functional bacterial plasmids in vitro. Proceedings of the National Academy of Sciences of the USA 70, 3240-3244.
12. Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society 1985 Degenerative neurologic disease in patients formerly treated with human growth hormone. Report of the Committee on Growth Hormone Use of the Lawson Wilkins Pediatric Endocrine Society, May 1985. Journal of Pediatrics 107, 10-12.
13. Daya S 2002 Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility and Sterility 77, 711-714.
14. Donini P, Montezemolo R 1949 Anterior pituitary gonadotrophin and human prehypophysio-like gonadotrophin. Rassegna di Clinica, Terapia e Scienze Affini. A publication of the Biologic Laboratories of the Istituto Serono 48, 3-28.
15. Driebergen R, Baer G 2003 Quantification of follicle stimulating hormone (follitropin alfa): is in-vivo bioassay still relevant in the recombinant age? Current Medical Research and Opinion 19, 41-46.
16. Eshkol A, Lunenfeld B 1967 Purification and separation of follicle stimulating hormone (FSH) and luteinizing hormone (LH) from human menopausal gonadotrophin (HMG) Part III. Acta Endocrinologica 54, 919.
17. European Communities (EC) 1986 Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of European Communities L 358, 18/12/1986, 1-28.
18. European Pharmacopeia 2002, 2003 Council of Europe, Strasbourg, France.
19. European Recombinant Human LH Study Group 1998 Recombinant human luteinising hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)-induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. Journal of Clinical Endocrinology and Metabolism 83, 1507-1514.
20. Falconer H, Andersson E, Aenesen A, Fried G 2005 Follicle-stimulating hormone receptor polymorphisms in a population of infertile women. Acta Obstetricia et Gynecologica Scandinavica 84, 806-811.
21. Fedorcsak D, Dale PO, Storeng R et al. 2004 Impact of overweight and underweight on assisted reproduction treatment. Human Reproduction 19, 2523-2528.
22. Galloway JA, Chance RE 1994 Improving insulin therapy: achievements and challenges. Hormone Metabolic Research 26, 591-598.
23. Gervais A, Hammel Y-A, Baer G et al. 2003 Glycosylation of human recombinant gonadotrophins: characterisation and batch-to-batch consistency. Glycobiology 13, 179-189.
24. Giudice E, Crisci C, Altarocca M et al. 2001 Characterisation of a partially purified human menopausal gonadotrophin preparation. Journal of Clinical Research 4, 27-34.
25. Giudice E, Crisci C, Eshkol A et al. 1994 Composition of commercial gonadotrophin preparations extracted from human postmenopausal urine: characterisation of non-gonadotrophin proteins. Human Reproduction 9, 2291-2299.
26. Gordon K 2002 New developments in gonadotrophin pharmacology. Reproductive BioMedicine Online 5, 259-264.
27. Hermentin P, Witzel R, Schwick-Wagner P et al. 2002 N-glycan charge assay - an alternative for potency assays of therapeutic glycoproteins? Developments in Biological Standardisation (Basel) 111, 89-97.
28. Hillier S 1994 Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Human Reproduction 9, 188-191.
29. Hugues JN, Barlow DW, Rozenwaks Z et al. 2003 Improvement in consistency of response to ovarian stimulation with recombinant human follicle stimulating hormone resulting from a new method of calibrating the therapeutic preparation. Reproductive BioMedicine Online 6, 185-190.
30. Humaidan P, Bungum M, Bungum L, Ydling Andersen C 2004 Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH. Reproductive BioMedicine Online 8, 635-643.
31. Katzman PA, Godfrid M, Cain CK et al. 1943 The preparation of chorionic gonadotropin by chromatographic adsorption. Journal of Biological Chemistry 148, 501-507.
32. Lee CA 1998 The natural history of HIV disease in haemophilia. Blood Review 12, 135-144.
33. Loumaye E, Engrand P, Shoham Z et al. 2003 Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Human Reproduction 18, 314-322.
34. Loumaye E, Campbell R, Salat-Baroux J 1995 Human follicle-stimulating hormone produced by recombinant DNA technology: a review for clinicians. Human Reproduction Update 1, 188-199.
35. Ludwig M, Felberbaum R, Diedrich K et al. 2002 Ovarian stimulation: from basic science to clinical application. Reproductive BioMedicine Online 5 (suppl. 1), 73-86.
36. Lunenfeld B 2002 Development of gonadotrophins for clinical use. Reproductive BioMedicine Online 4 (suppl. 1), 11-17.
37. Marrs R, Meldrum D, Muasher S et al. 2004 Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reproductive BioMedicine Online 8, 175-182.
38. Mulders JW, Derksen M, Swolfs A et al. 1997 Prediction of the invivo biological activity of human recombinant follicle stimulating hormone using quantitative isoelectric focusing. Biologicals 25, 269-281.
39. Olijve W, De Boer W, Mulders J et al. 1996 Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®). Molecular Human Reproduction 2, 371-382.
40. Peñarrubia J, Fábregues F, Manau D et al. 2005 Previous cycle cancellation due to poor follicular development as a predictor of ovarian response in cycles stimulated with gonadotrophin-releasing hormone agonist- gonadotrophin treatment. Human Reproduction 20, 622-628.
41. Raben MS 1957 Preparation of growth hormone from pituitaries of man and monkey. Science 125, 883-884.
42. Seamon KB 1998 Specifications for biotechnology-derived protein drugs. Current Opinion in Biotechnology 9, 319-325.
43. Schroder AK, Katalinic A, Dietrich K, Ludwig M 2004 Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reproductive BioMedicine Online 8, 600-606.
44. Shoham Z 2002 The clinical therapeutic window for luteinising hormone in controlled ovarian stimulation. Fertility and Sterility 77, 1170-1177.
45. Spandorfer SD, Kump L, Goldschlag D et al. 2004 Obesity and in vitro fertilization: negative influences on outcome. Journal of Reproductive Medicine 49, 973-977.
46. Steelman SL, Pohley FM 1953 Assay of the follicle-stimulating hormone based on the augmentation with human chorionic gonadotrophin. Endocrinology 53, 604-616.
47. Ulloa-Aguirre A, Espinoza R, Damian-Matsumura P et al. 1988 Immunological and biological potencies of the different molecular species of gonadotrophins. Human Reproduction 3, 491-501.
48. van de Weijer B, Mulders J, Bos E et al. 2003 Compositional analyses of a human menopausal preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive BioMedicine Online 7, 547-557.
49. Yarram SJ, Jenkins J, Cole LA et al. 2004 Epidermal growth factor contamination and concentrations of intact human chorionic gonadotropin in commercial preparations. Fertility and Sterility 82, 232-233.
50. Yeko T, Pasqualini SR, Alam V, Tredway D 2004 Cumulative ovulation and pregnancy rates according to recombinant human follicle stimulating hormone (r-hFSH) dosing: comparison of a new formulation of follitropin alfa in vials versus the standard formulation of follitropin alfa in ampoules. Fertility and Sterility 82, S119.
51. Wittemer C, Ohl J, Bailly M et al. 2000 Does body mass index of infertile woman have an impact of IVF procedure and outcome?. Journal of Assisted Reproduction and Genetics 17, 547-552.